CHE

Chemed Completes $85M Acquisition of Covenant Health Hospice Operations

Vitas Healthcare Corporation, a subsidiary of Chemed Corporation, has successfully completed the acquisition of all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc. (Covenant) for a total purchase price of $85 million. This transaction, which was structured as an asset purchase, includes the hospice operations spanning the panhandle of Florida and Alabama, covering markets in Florida such as Tallahassee, Marianna, Fort Walton Beach, Panama City, Crestview, and Pensacola, as well as the Dothan and Mobile/Daphne markets in Alabama.

The transaction, announced on March 13, 2024, has now closed effectively as of April 17, 2024. Chemed Corporation, listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, operates two wholly owned subsidiaries: Vitas Healthcare and Roto-Rooter. Vitas is recognized as the nation's largest provider of end-of-life hospice care, while Roto-Rooter is the leading provider of plumbing and drain cleaning services in the nation.

It remains to be seen how this recent acquisition will impact Chemed Corporation's financial performance and market position in the future. Following these announcements, the company's shares moved -1.0%, and are now trading at a price of $603.61. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS